港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

勁方醫藥-B

28.940

+2.94011.31%

成交量：1,159.60萬

成交額：3.48億

市值：107.08億

市盈率：-1.10

高：33.720

開：27.700

低：26.040

收：26.000

52周最高：50.200

52周最低：19.600

股本：3.70億

香港流通股本：3.38億

量比：3.67

換手率：3.43%

股息：- -

股息率：- -

每股收益(LYR):-26.205

淨資產收益率：--

總資產收益率：-30.27%

市淨率：-3.56

市盈率(LYR):-1.10

市銷率: 48.63

資料載入中...

總覽公司新聞資訊公告

勁方醫藥(02595.HK)將於AACR年會展示三款產品臨床前研究數據

阿斯达克财经

勁方醫藥-B(02595)將於2026年AACR年會上展示三款RAS通路相關的大、小分子靶向藥臨床前研究數據

勁方醫藥(02595)午後漲22.54% 公司宣佈三款新藥入選AACR壁報環節

勁方醫藥－Ｂ(02595)股價上升9.538%，現價港幣$28.48

阿斯达克财经

Wellington Management Group LLP增持勁方醫藥-B(02595)252.42萬股每股作價約27.26港元

勁方醫藥－Ｂ(02595)股價上升5.213%，現價港幣$28.66

阿斯达克财经

勁方醫藥－Ｂ(02595)出現大手成交46.3萬股，成交價$28.29，涉資1.31千萬

阿斯达克财经

勁方醫藥－Ｂ(02595)股價下跌8.184%，現價港幣$30.74

阿斯达克财经

方興，未艾 | 對話勁方醫藥：喧囂中的RAS創新與中國樣本

劲方医药GenFleet

勁方醫藥-B03月09日獲主力加倉1300.8萬元

港股異動 | 勁方醫藥-B(02595)升逾11% 公司將獲納入港股通預計GFH375治療結果將於國際學術會議發布

方興，未艾 | 對話勁方醫藥：喧囂中的RAS創新與中國樣本

勁方醫藥-B03月06日獲主力加倉316.0萬元

勁方醫藥-B（02595）2月無新增發行或股份變動

每日沽空追蹤 | 勁方醫藥-B 03月05日沽空量成交11.04萬股，沽空比例為16.41%

勁方醫藥-B盤中異動早盤股價大跌5.03%

信達生物、勁方醫藥等藥企密集報喜，多款創新藥迎來突破

每日沽空追蹤 | 勁方醫藥-B 03月02日沽空量成交10.92萬股，沽空比例為25.5%

勁方醫藥-B(02595)：GFH375獲得國內首個KRAS G12D抑制劑治療非小細胞肺癌的突破性療法認定

勁方醫藥-B（02595）GFH375獲中國首個KRAS G12D抑制劑突破性療法認定

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/02595/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"勁方醫藥-B","latestPrice":28.94,"timestamp":1773994128006,"preClose":26,"halted":0,"volume":11596000,"delay":0,"changeRate":0.11307692307692313,"floatShares":338000000,"shares":370000000,"eps":-26.20482,"marketStatus":"休市中","change":2.94,"latestTime":"03-20 16:08:48","open":27.7,"high":33.72,"low":26.04,"amount":347763380,"amplitude":0.295385,"askPrice":28.96,"askSize":2000,"bidPrice":28.94,"bidSize":19800,"shortable":3,"etf":0,"ttmEps":-2.744,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":7,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":26,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":3.6737034119222813,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-30.27%","roe":"--","lyrEps":-26.20482,"volumeRatio":3.6737034119222813,"shares":370000000,"dividePrice":0,"high":33.72,"amplitude":0.295385,"preClose":26,"low":26.04,"week52Low":19.6,"pbRate":"-3.56","psRate":"48.63","week52High":50.2,"institutionHeld":0,"latestPrice":28.94,"committee":0.816514,"eps":-26.20482,"divideRate":0,"volume":11596000,"delay":0,"ttmEps":-2.744,"open":27.7,"prevYearClose":23.78,"prevWeekClose":29.42,"prevMonthClose":27.4,"prevQuarterClose":23.78,"fiveDayClose":29.42,"twentyDayClose":28.72,"sixtyDayClose":26.74,"earningDate":1774281600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[{"date":"2026-03-24","symbol":"02595","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774315800000,"name":null,"time":"","dateTimestamp":1774281600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1769184000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2026-03-20","current":-10.546647,"percent":0.586777,"low":-19.62221,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"high":-7.530857,"avg":-11.034508,"sd":2.619015,"marketCap":10718410272},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-21","current":-10.329745,"twenty":-18.396816,"median":-10.725216,"eighty":-10.005136,"marketCap":10481375629},{"date":"2025-11-28","current":-10.423287,"twenty":-18.142029,"median":-10.678396,"eighty":-10.044836,"marketCap":10614707615},{"date":"2025-12-05","current":-10.100425,"twenty":-16.087956,"median":-10.631034,"eighty":-10.044836,"marketCap":10303599646},{"date":"2025-12-12","current":-10.212238,"twenty":-13.008301,"median":-10.584309,"eighty":-10.020393,"marketCap":10436931633},{"date":"2025-12-19","current":-9.790532,"twenty":-12.136764,"median":-10.450758,"eighty":-9.957409,"marketCap":10029528340},{"date":"2025-12-24","current":-8.945585,"twenty":-11.809112,"median":-10.416014,"eighty":-9.900509,"marketCap":9192499756},{"date":"2026-01-02","current":-8.020182,"twenty":-11.73453,"median":-10.320373,"eighty":-9.861601,"marketCap":8273990514},{"date":"2026-01-09","current":-11.588563,"twenty":-11.683046,"median":-10.309663,"eighty":-9.776189,"marketCap":11985064146},{"date":"2026-01-16","current":-11.693807,"twenty":-11.67863,"median":-10.369243,"eighty":-9.793132,"marketCap":12133210798},{"date":"2026-01-23","current":-10.361602,"twenty":-11.605818,"median":-10.329745,"eighty":-9.783265,"marketCap":10740632270},{"date":"2026-01-30","current":-10.919089,"twenty":-11.483053,"median":-10.385171,"eighty":-9.793132,"marketCap":11370255541},{"date":"2026-02-06","current":-11.146899,"twenty":-11.598147,"median":-10.450758,"eighty":-9.8258,"marketCap":11636919514},{"date":"2026-02-13","current":-10.659945,"twenty":-11.483053,"median":-10.58187,"eighty":-9.869606,"marketCap":11192479558},{"date":"2026-02-20","current":-10.145441,"twenty":-11.446311,"median":-10.573435,"eighty":-9.881527,"marketCap":10636929613},{"date":"2026-02-27","current":-9.574146,"twenty":-11.38719,"median":-10.509847,"eighty":-9.836956,"marketCap":10148045662},{"date":"2026-03-06","current":-8.841756,"twenty":-11.29428,"median":-10.416014,"eighty":-9.744297,"marketCap":9296202413},{"date":"2026-03-13","current":-10.316011,"twenty":-11.38719,"median":-10.450758,"eighty":-9.761464,"marketCap":10896186254},{"date":"2026-03-20","current":-10.186272,"twenty":-11.29428,"median":-10.385171,"eighty":-9.744297,"marketCap":10718410272}],"updateTime":1774178454659},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621716099","title":"勁方醫藥(02595.HK)將於AACR年會展示三款產品臨床前研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2621716099","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621716099?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 15:26","pubTimestamp":1774164360,"startTime":"0","endTime":"0","summary":"劲方医药－Ｂ(02595.HK) 公布，公司将于2026年AACR年会壁报环节展示GFH276(非降解性分子胶)、GFS784(新型偶联药物，连接功能性抗体及机制协同性靶向药载荷)、GFH603(类分子胶共价变构激活剂)三款产品的临床前研究数据。本届AACR年会将于4月17日至22日日在美国圣地亚哥举行，公司参会壁报将分别于4月19日及21日展示。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-20 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250925155657502_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250925155657502_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511163/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511163/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02595","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"2620731689","title":"勁方醫藥-B(02595)將於2026年AACR年會上展示三款RAS通路相關的大、小分子靶向藥臨床前研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731689","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620731689?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 21:33","pubTimestamp":1774013615,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，公司将于2026年AACR年会壁报环节展示GFH276(非降解性分子胶)、GFS784(新型偶联药物，连接功能性抗体及机制协同性靶向药载荷)、GFH603(类分子胶共价变构激活剂)三款产品的临床前研究数据。公司RAS疗法矩阵聚焦多种选择性和泛RAS抑制剂，亦持续关注RAS通路重要共突变的潜在靶点;该矩阵包含多元分子形态、多机制RAS通路相关的大、小分子靶向药。届AACR年会将于2026年4月17日至22日在美国圣地亚哥举行，公司参会壁报将分别于4月19日和4月21日展示。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416899.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02595","BK1574","09939","BK1515","159938"],"gpt_icon":0},{"id":"2620713202","title":"勁方醫藥(02595)午後漲22.54% 公司宣佈三款新藥入選AACR壁報環節","url":"https://stock-news.laohu8.com/highlight/detail?id=2620713202","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620713202?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 13:36","pubTimestamp":1773984997,"startTime":"0","endTime":"0","summary":"金吾财讯 | 劲方医药 午后大幅拉升，截至发稿，报31.86港元，涨22.54%，成交额1.49亿港元。消息面上，据劲方医药官微消息，公司宣布其管线中三款新药的临床前研究成果入选2026年美国癌症研究协会壁报环节，今年AACR年会将于2026年4月17日至22日在美国圣地亚哥举行。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1161","02595","159938","BK1515","BK1574"],"gpt_icon":0},{"id":"2620206058","title":"勁方醫藥－Ｂ(02595)股價上升9.538%，現價港幣$28.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2620206058","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620206058?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 10:35","pubTimestamp":1773974100,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午10:35比前收市价上升9.538%，现股价为港币$28.48。至目前为止，今日最高价为$28.48，而最低价为$26.04。总成交量为82.04万股，总成交金额为港币$2.268千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603201532/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2603201532/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","BK1515","BK1161","02595","BK1574","09939"],"gpt_icon":0},{"id":"2620247374","title":"Wellington Management Group LLP增持勁方醫藥-B(02595)252.42萬股 每股作價約27.26港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247374","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247374?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 19:53","pubTimestamp":1773921202,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月17日，Wellington Management Group LLP增持劲方医药-B(02595)252.42万股，每股作价27.259港元，总金额约为6880.72万港元。增持后最新持股数目约为1776.94万股，持股比例为5.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","02595","159938","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2620831892","title":"勁方醫藥－Ｂ(02595)股價上升5.213%，現價港幣$28.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2620831892","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620831892?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 10:35","pubTimestamp":1773801300,"startTime":"0","endTime":"0","summary":"[上升股]劲方医药－Ｂ(02595) 股价在上午10:35比前收市价上升5.213%，现股价为港币$28.66。至目前为止，今日最高价为$28.66，而最低价为$27.36。总成交量为284.06万股，总成交金额为港币$7.77千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318739/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318739/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","BK1161","02595","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2619458312","title":"勁方醫藥－Ｂ(02595)出現大手成交46.3萬股，成交價$28.29，涉資1.31千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458312","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619458312?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 15:45","pubTimestamp":1773647100,"startTime":"0","endTime":"0","summary":"[大手成交]劲方医药－Ｂ(02595)在下午03:45出现大手成交，成交量为46.3万，成交价为港币$28.29，涉资1.31千万。至目前为止，股价跌3.807%，今日最高价为$31.58，而最低价为$27.14，总成交量为370.856万股，总成交金额港币$1.071亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603167512/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603167512/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02595","BK1574","BK1515","09939","159938","BK1161"],"gpt_icon":0},{"id":"2618022109","title":"勁方醫藥－Ｂ(02595)股價下跌8.184%，現價港幣$30.74","url":"https://stock-news.laohu8.com/highlight/detail?id=2618022109","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618022109?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 13:05","pubTimestamp":1773291900,"startTime":"0","endTime":"0","summary":"[下跌股]劲方医药－Ｂ(02595) 股价在下午01:05比前收市价下跌8.184%，现股价为港币$30.74。至目前为止，今日最高价为$35.5，而最低价为$30.74。总成交量为144.96万股，总成交金额为港币$4.84千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603122293/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603122293/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02595","09939","BK1515","BK1161","BK1574","159938"],"gpt_icon":0},{"id":"2618962937","title":"方興，未艾 | 對話勁方醫藥：喧囂中的RAS創新與中國樣本","url":"https://stock-news.laohu8.com/highlight/detail?id=2618962937","media":"劲方医药GenFleet","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618962937?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 08:36","pubTimestamp":1773102997,"startTime":"0","endTime":"0","summary":"备受市场关注的RAS赛道正是典型缩影。其管线中的氟泽雷塞为国内首个上市的KRAS G12C抑制剂；其 KRAS G12D 抑制剂单药研究、小分子Pan RAS抑制剂以及Pan RAS ADC的临床进度，也都位居全球前列。以扎实管线与高效执行，劲方医药在这波行业热潮中占据关键位置，也借此获得资本市场高度认可。氨基观察通过专访劲方医药董事长吕强，试图还原一家本土创新药企的成长逻辑与长期答案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031008390897ab6e4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031008390897ab6e4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","02595","09939","BK1574"],"gpt_icon":0},{"id":"2618623355","title":"勁方醫藥-B03月09日獲主力加倉1300.8萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623355","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623355?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 16:15","pubTimestamp":1773044108,"startTime":"0","endTime":"0","summary":"03月09日, 劲方医药-B股价涨20.80%，报收30.32元，成交金额1.8亿元，换手率1.87%，振幅24.70%，量比7.74。劲方医药-B今日主力资金净流入1300.8万元，连续7日净流入，上一交易日主力净流入316.0万元。该股近5个交易日上涨9.16%，主力资金累计净流入2129.6万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流入2252.9万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161522a45ad28b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161522a45ad28b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","09939","02595","BK1574"],"gpt_icon":0},{"id":"2618180316","title":"港股異動 | 勁方醫藥-B(02595)升逾11% 公司將獲納入港股通 預計GFH375治療結果將於國際學術會議發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2618180316","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618180316?lang=zh_tw&edition=fundamental","pubTime":"2026-03-09 09:57","pubTimestamp":1773021454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B涨超11%，截至发稿，涨9.96%，报27.6港元，成交额4006.33万港元。近日，劲方医药-B公告称，公司GFH375获得国内首个KRAS G12D抑制剂治疗非小细胞肺癌的突破性疗法认定。值得关注的是，GFH375治疗KRAS G12D突变型实体瘤及NSCLC的初步研究数据，曾在2025年登陆美国临床肿瘤学会年会及世界肺癌大会的突破性研究摘要 和现场口头报告，GFH375治疗NSCLC患者的最新研究结果预计将在今年国际学术会议发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","VXUS","VT","BK1161","159938","BK4588","BK1574","BK4585","BK1515","02595"],"gpt_icon":0},{"id":"2618612686","title":"方興，未艾 | 對話勁方醫藥：喧囂中的RAS創新與中國樣本","url":"https://stock-news.laohu8.com/highlight/detail?id=2618612686","media":"氨基观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618612686?lang=zh_tw&edition=fundamental","pubTime":"2026-03-08 20:08","pubTimestamp":1772971680,"startTime":"0","endTime":"0","summary":"备受市场关注的RAS赛道正是典型缩影。其管线中的氟泽雷塞为国内首个上市的KRAS G12C抑制剂；其 KRAS G12D 抑制剂单药研究、小分子Pan RAS抑制剂以及Pan RAS ADC的临床进度，也都位居全球前列。以扎实管线与高效执行，劲方医药在这波行业热潮中占据关键位置，也借此获得资本市场高度认可。氨基观察通过专访劲方医药董事长吕强，试图还原一家本土创新药企的成长逻辑与长期答案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308203656a45825cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260308203656a45825cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02595","09939","BK1161","BK1515"],"gpt_icon":0},{"id":"2617765260","title":"勁方醫藥-B03月06日獲主力加倉316.0萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617765260","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617765260?lang=zh_tw&edition=fundamental","pubTime":"2026-03-06 16:15","pubTimestamp":1772784910,"startTime":"0","endTime":"0","summary":"03月06日, 劲方医药-B股价涨7.91%，报收25.10元，成交金额2674.4万元，换手率0.32%，振幅8.94%，量比1.11。劲方医药-B今日主力资金净流入316.0万元，连续6日净流入，上一交易日主力净流入47.5万元。该股近5个交易日下跌9.05%，主力资金累计净流入923.1万元；近20日主力资金累计净流入1045.3万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161521a6aa28e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161521a6aa28e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02595","BK1574","09939","BK1515"],"gpt_icon":0},{"id":"1130194745","title":"勁方醫藥-B（02595）2月無新增發行或股份變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1130194745","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130194745?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 16:36","pubTimestamp":1772699803,"startTime":"0","endTime":"0","summary":"2026年3月5日，劲方医药科技（上海）股份有限公司披露截至2026年2月28日的证券变动月报表。公司本月无新增发行或股份变动，股本结构与上月相比保持稳定。公司注册及已发行股本仍为人民币37,036,663元，合计已发行338,029,020股H股及32,337,610股未上市股份，总计370,366,630股。公司表示将持续遵守相关监管规定，并确保信息披露的合规与透明。本次公告由公司联席公司秘书张巍签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"gpt_icon":0},{"id":"2617483105","title":"每日沽空追蹤 | 勁方醫藥-B 03月05日沽空量成交11.04萬股，沽空比例為16.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617483105","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617483105?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 16:30","pubTimestamp":1772699433,"startTime":"0","endTime":"0","summary":"劲方医药-B北京时间03月05日，跌1.02%，卖空量成交11.04万股，较上一交易日减少74.43%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163424a6a5d977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305163424a6a5d977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","02595","BK1574","09939"],"gpt_icon":0},{"id":"2617091550","title":"勁方醫藥-B盤中異動 早盤股價大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617091550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617091550?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 10:12","pubTimestamp":1772590352,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘10时12分，劲方医药-B股票出现波动，股价快速下跌5.03%。截至发稿，该股报23.780港元/股，成交量16.54万股，换手率0.05%，振幅6.07%。劲方医药-B股票所在的药品行业中，整体跌幅为0.48%。其相关个股中，德琪医药-B、开拓药业-B、凯莱英涨幅较大，振幅较大的相关个股有德琪医药-B、凯莱英、宝济药业-B，振幅分别为9.72%、8.80%、6.67%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304101232a4490585&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304101232a4490585&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09939","BK1515","02595"],"gpt_icon":0},{"id":"2617550772","title":"信達生物、勁方醫藥等藥企密集報喜，多款創新藥迎來突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2617550772","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617550772?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 09:43","pubTimestamp":1772588603,"startTime":"0","endTime":"0","summary":"3月2日，医药领域迎来暖意融融的好消息，多家药企集中发布公告，披露创新药研发与审批的重大进展，涉及新适应证获批、突破性疗法认定、临床许可等。此外，根据CDE网站公示，多款创新药获得临床许可。此次多家药企集中迎来利好，正是我国医药创新能力持续提升的生动体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304094641a69fc774&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304094641a69fc774&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828631.EUR","BK1515","LU0455707207.USD","LU0502904849.HKD","LU2328871848.SGD","LU1969619763.USD","BK1574","LU2242644610.SGD","LU2097828714.EUR","HK0000165453.HKD","09939","LU2097828557.USD","02595","LU2097828474.EUR","01801","BK1589","BK1161","BK1583","LU2488822045.USD","LU2097828805.USD","06978"],"gpt_icon":0},{"id":"2616382238","title":"每日沽空追蹤 | 勁方醫藥-B 03月02日沽空量成交10.92萬股，沽空比例為25.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616382238","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616382238?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 16:30","pubTimestamp":1772440235,"startTime":"0","endTime":"0","summary":"劲方医药-B北京时间03月02日，跌1.17%，卖空量成交10.92万股，较上一交易日减少72.34%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163502a730c7dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163502a730c7dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09939","02595","BK1515"],"gpt_icon":0},{"id":"2616877444","title":"勁方醫藥-B(02595)：GFH375獲得國內首個KRAS G12D抑制劑治療非小細胞肺癌的突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2616877444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616877444?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 08:04","pubTimestamp":1772409867,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 公布，口服KRAS G12D 抑制剂GFH375已被国家药品监督管理局药品审评中心纳入突破性疗法认定名单，拟用于至少接受过一种系统性治疗的KRAS G12D突变型非小细胞肺癌患者。本次认定基于GFH375X1101研究中NSCLC患者的治疗结果，I/II期试验数据展现了GFH375单药治疗KRAS G12D突变型NSCLC的同类最佳疗效、且整体安全性╱耐受性可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408736.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","BK1515","02595","BK1161","BK1574"],"gpt_icon":0},{"id":"1198434611","title":"勁方醫藥-B（02595）GFH375獲中國首個KRAS G12D抑制劑突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=1198434611","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198434611?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 08:02","pubTimestamp":1772409735,"startTime":"0","endTime":"0","summary":"劲方医药（上海）有限公司旗下创新药物GFH375近日获得中国国家药品监督管理局药品审评中心授予的突破性治疗药物程序认定。这是国内首个针对KRAS G12D突变抑制剂的突破性疗法认定，标志着公司在肿瘤靶向治疗领域取得重大进展。GFH375作为高选择性KRAS G12D口服小分子抑制剂，通过不可逆结合方式特异性抑制KRAS G12D蛋白活性。突破性治疗药物程序将加速GFH375的临床开发和审评进程，为存在KRAS G12D突变的晚期实体瘤患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":104,"code":"91000000","status":"200"}]}}